Preview

Педиатрическая фармакология

Расширенный поиск

ВАКЦИНАЦИЯ НЕДОНОШЕННЫХ И МАЛОВЕСНЫХ ДЕТЕЙ

https://doi.org/10.15690/pf.v10i4.752

Полный текст:

Аннотация

Статья посвящена вакцинации недоношенных/маловесных детей, что является крайне актуальным вопросом — эти дети наиболее подвержены инфекционным болезням, в том числе контролируемым, но их вакцинация пугает специалистов своими возможными нежелательными реакциями со стороны еще незрелого организма на введение иммунотропного вещества. Автором показаны особенности иммунного ответа недоношенных новорожденных, в частности Т-клеточного звена, что необходимо учитывать при вакцинации. Особое внимание уделено безопасности вакцин — риску развития эпизодов апноэ с/без брадикардии, их влиянию на частоту обструктивных эпизодов, воздействию на организм одновременного введения нескольких вакцин. Кроме того, в статье обсуждаются вопросы иммуногенности и реактогенности различных вакцин при их введении маловесным детям.

Об авторе

В. К. Таточенко
Научный центр здоровья детей РАМН, Москва, Российская Федерация
Россия

доктор медицинских наук, профессор, главный научный сотрудник НЦЗД РАМН





Список литературы

1. Langkamp D. L., Davis J. P. Increased risk of reported pertussis and hospitalization associated with pertussis in low birth weight children. J Pediatr. 1996; 128: 654–9.

2. Конъюгированная пневмококковая вакцина для иммунизации детей — рекомендации ВОЗ. Педиатрическая фармакология. 2007; 4 (5): 6–10.

3. Намазова Л.С., Ботвиньева В.В., Гайворонская А.Г., Филянская Е.Г. Изучение эффективности и безопасности вакцинации против гемофильной инфекции типа b у детей раннего возраста. Педиатрическая фармакология. 2008; 5 (5): 10–12.

4. Намазова-Баранова Л.С. Научные исследования и инфраструктура платформы «Педиатрия». Педиатрическая фармакология. 2012; 9 (4): 15–24.

5. Levy O., Zarember K. A., Roy R. M., et al. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol. 2004; 173 (7): 4627–4634.

6. Студеникин В. М. Становление лимфоидной системы и особенности мембранных рецепторов иммунокомпетентных клеток в раннем онтогенезе. Автореф. дис. … докт. мед. наук. М., 1997.

7. Berrington J. E., Barge D., Fenton A. C., Cant A. J., Spickett G. P. Lymphocyte subsets in term and significantly preterm UK infants in the first year of life analysed by single platform flow cytometry. Clin Exp Immunol. 2005; 140 (2): 289–292.

8. Турти Т.В., Семикина Е.Л., Намазова Л.C. Особенности экспрессии цитокиновых рецепторов на мембране лимфоцитов у новорожденных детей. Вопросы современной педиатрии. 2006; 5 (1): 5–23.

9. Klein N. P., Gans H. A., Sung P. et al. Preterm infants' T cell responses to inactivated poliovirus vaccine. J Infect Dis. 2010; 201 (2): 214–222.

10. Baxter D. Impaired functioning of immune defenses to infection in premature and term infants and their implications for vaccination. Human Vaccines. 2010; 6 (6): 494–505.

11. Esposito S., Fumagalli M., Principi N. Immunogenicity, safety and tolerability of vaccinations in premature infants. Expert Rev Vaccines. 2012; 11 (10): 1199–209.

12. van den Berg J. P., Westerbeek E. A. M., van der Klis F. R. M. et al. Transplacental transport of IgG antibodies to preterm infants: A review of the literature. Hum Vaccin. 2011; 87 (2): 67–72.

13. Bonhoeffer J., Siegrist C.-A., Heath P. T. Immunisation of premature infants. Arch Dis Child. 2006; 9: 929–935.

14. Sen S., Cloete Y., Hassan K., Buss P. Adverse events following vaccination in premature infants. Acta Paediatr. 2001; 90 (8): 916–920.

15. D’Angio C. Active immunization of premature and low birthweight infants: A review of immunogenicity, efficacy, and tolerability. Paediatr Drugs. 2007; 9 (1): 17–32.

16. Schloesser R., Fischer D., Otto W., Rettwitz-Volk W., Herden P., Zielen S. Safety and immunogenicity of an acellular pertussis vaccine in premature infants. Pediatrics. 1999; 103 (5): e60.

17. Vazquez L., Garcia F., Ruttimann R. et al. Immunogenicity and reactogenicity of DTPa-HBV–IPV/Hib vaccine as primary and booster vaccination in low-birth-weight premature infants. Acta Paediatr. 2008; 97 (9): 1243–9.

18. Furck A. K., Richter J. W., Kattner E. Very low birth weight infants have only few adverse events after timely immunization. J Perinatol. 2010; 30 (2): 118–21.

19. Hacking D. F., Davis P. G., Wong E., Wheeler K., McVernon J. Frequency of respiratory deterioration after immunisation in preterm infants. J Paediatr. Child Health. 2010; 46 (12): 742–748.

20. Klein N. P., Massolo M. L., Greene J., Dekker C. L., Black S., Escobar G. J. et al. Risk factors for developing apnea after immunization in the Neonatal Intensive Care Unit. Pediatrics. 2008; 121 (3): 463–9.

21. Carbone T., McEntire B., Kissin D. еt al. Absence of an increase in cardiorespiratory events after diphtheria-tetanus-acellular pertussis immunization in preterm infants: a randomized, multicenter study. Pediatrics. 2008; 121 (5): e1085–90.

22. Clifford V., Crawford N. W., Royle J. et al. Recurrent apnoea post immunisation: Informing re-immunisation policy. Vaccine. 2011; 29 (34): 5681–5687.

23. Schulzke S., Heininger U., Lucking-Famira M., Fahnenstich H. Apnoea and bradycardia in preterm infants following immunization with pentavalent or hexavalent vaccines. Eur J Pediatr. 2005; 164 (7): 432–5.

24. Pfister R. E., Aeschbach V., Niksic-Stuber V., Martin B. C., Siegrist C.-A. Safety of DTaP-based combined immunization in verylowbirth-weight premature infants: Frequent but mostly benign cardiorespiratory events. J Pediatr. 2004; 145 (1): 58–66.

25. Botham S. J., Isaacs D., Henderson-Smart D. J. Incidence of apnoea and bradycardia in preterm infants following DTPw and Hib immunization: a prospective study. J Paediatr Child Health. 1997; 33 (5): 418–21.

26. American Academy of Pediatrics, Committee on Infectious Diseases. Red Book. 19th ed. Evanston, IL: AAP. 1982. Р. 200–2.

27. Pourcyrous M., Korones S., Arheart K. I., Bada H. S. Primary immunization of premature infants with gestational age < 35 weeks: cardiorespiratory complications and C-reactive rotein responses associated with administration of single and multiple separate vaccines simultaneously. J Pediatr. 2007; 151: 167–72.

28. Mullooly J. P., Schuler R., Mesa J. et al. Wheezing lower respiratory disease and vaccination of premature infants. Vaccine. 2011; 29 (44): 611–7617.

29. Aued Perin М. С., Schlindwein С. F., de Moraes-Pinto M. I. et al. Immune response to tetanus booster in infants aged 15 months born prematurely with very low birth weight. Vaccine. 2012; 30 (46): 6521–6526.

30. Slack M. H., Schapira D., Thwaites R. J. et al. Acellular pertussis vaccine given by accelerated schedule: response of preterm infants. Arch Dis Child Fetal Neonatal Ed. 2004; 89 (1): F57–60.

31. Esposito S., Faldella G., Giammanco A. et al. Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants. Vaccine. 2002; 20 (23–24): 2928–2932.

32. Vermeulen F., Verscheure V., Damis E. et al. Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines. Clin Vaccine Immunol. 2010; 17 (2): 258–262.

33. Slack M. H., Cade S., Schapira D. DT5aP-Hib-IPV and MCC vaccines: preterm infants' response to accelerated immunisation. Arch Dis Child. 2005; 90 (4): 338–341.

34. Adenyi-Jones S. C., Faden H., Ferdon M. B. et al. Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J Pediatr. 1992; 120 (5): 686–689.

35. D'Angio C. T., Maniscalco W. M., Pichichero M. E. Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations. Pediatrics. 1995; 96 (1 Pt. 1): 18–22.

36. Losonsky G. A., Wasserman S. S., Stephens I. et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics. 1999; 103 (2): E14.

37. Omenaca F., Garcia-Sicilia J., Garcia-Corbeira P., Boceta R. et al. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics. 2005; 16 (6): 1292–8.

38. Kristensen K., Gyhrs A., Lausen B. et al. Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. Pediatr Infect Dis J. 1996; 15 (6): 525–529.

39. Heath P. T., Booy R., McVernon J. et al. Hib vaccination in infants born prematurely. Arch Dis Child. 2003 Mar; 88 (3): 206–10.

40. Omenaca F., Garcia-Sicilia J., Garcia-Corbeira P. et al. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheriatetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine. Pediatrics. 2007; 119 (1): e179–85.

41. Omenaca F., Garcia-Sicilia J., Boceta R. et al. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely. Pediatr Infect Dis J. 2007 Sep; 26 (9): 824–9.

42. Szynczewska Е., Chlebna-Sokol D. Immunogenicity and safety of heptavalent conjugate vaccine against Streptococcus pneumonia in pre-term polish infants. Vaccine. 2011; 29: 7107– 7113.

43. Esposito S., Pugnib L., Bosisa S. et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and fullterm infants. Vaccine. 2005; 23: 1703–1708.

44. D’Angio С. Т., Heyne R. J., ’Shea M. et al. Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birthweight, premature infants. Pediatr Infect Dis J. 2010; 29 (7): 1–7.

45. Shinefield H., Black S., Ray P. et al. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J. 2002; 21 (3): 182–6.

46. Ruckinger S., van der Linden M., von Kries1 R. et al. Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants. BMC Infectious Diseases. 2010; 10: 12. Doi: 10.1186/1471-2334-10-12.

47. Omenaca F., Merino J. M., Tejedor J. C. et al. Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine. Pediatrics. 2011; 128 (2): e290–298.

48. D'Angio C. T., Heyne R. J., Duara S. et al. Premature Infant Vaccine Collaborative. Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants. Pediatr Infect Dis J. 2011; 30 (7): 570–574.

49. Omenaca F., Sarlangue J., Szenborn L. et al. ROTA-054 Study Group Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European infants: a randomized Phase IIIb study. Pediatr Infect Dis J. 2012; 31 (5): 487–493.

50. Smith C. K., McNeal M. M., Meyer N. R. et al. Rotavirus shedding in premature infants following first immunization. Vaccine. 2011; 29 (45): 8141–8146.

51. D'Angio C. T., Boohene P. A., Mowrer A. et al. Measles-mumpsrubella and varicella vaccine responses in extremely preterm infants. Pediatrics. 2007; 119 (3): e574–579.


Для цитирования:


Таточенко В.К. ВАКЦИНАЦИЯ НЕДОНОШЕННЫХ И МАЛОВЕСНЫХ ДЕТЕЙ. Педиатрическая фармакология. 2013;10(4):30-36. https://doi.org/10.15690/pf.v10i4.752

For citation:


Tatochenko V.K. VACCINATION OF PREMATURE/LOW-BIRTH-WEIGHT CHILDREN. Pediatric pharmacology. 2013;10(4):30-36. (In Russ.) https://doi.org/10.15690/pf.v10i4.752

Просмотров: 576


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1727-5776 (Print)
ISSN 2500-3089 (Online)